$VVOS

Vivos Therapeutics, Inc.

Vivos Therapeutics is a medical technology and healthcare services company that provides oral appliances and treatments for breathing and sleep disorders, including obstructive sleep apnea and snoring. Its Vivos Method combines appliances with therapeutic protocols and may include adjunctive therapies. Products include its C.A.R.E. appliances, such as DNA, mRNA and mmRNA, as well as other oral appliances, diagnostic tools and services including home sleep testing, treatment navigation, billing support and myofunctional therapy. The Vivos Institute provides clinical education and training. Vivos makes money through appliance sales, fees for diagnostic and treatment services, and administrative and non-clinical support fees through management services organizations and dental service organizations. It also earns fees from training and support services for providers. Its business includes acquiring or managing sleep medical practices and collaborating with healthcare providers. Vivos is headquartered in Littleton, Colorado.

2
0
0

No SEC Form 4 filings for $VVOS in the last 30 days.

See all $VVOS insider activity →
Med

Vivos Therapeutics reports Q3 revenue growth, regains Nasdaq compliance

Vivos Therapeutics (VVOS) reported Q3 2026 revenue of $6.4M, up 24% from Q2 2026. Operating loss improved 18% YoY to $3.9M. Nine-month revenue rose 23% to $16.7M. Gross margin was 52% in Q3. Net loss was $2.0M, improved from $5.4M in Q3 2025. Cash fell to $0.2M. Nasdaq compliance regained.

SOD SCIENCES INC.: CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test

SOD Sciences and Vivos Therapeutics (VVOS) announced a strategic partnership. Vivos acquired an 11% stake in SOD and 50% ownership of its pseudohypoxia patent and test for $12M in convertible preferred stock. The companies will jointly market the ReBalU Protocol to Vivos's customers, targeting 500,000 chronic disease patients. SOD retains other patents and protocol rights.

VVOS sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning VVOS (Vivos Therapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.

Recent VVOS coverage spans corporate actions, mergers & acquisitions and earnings.

What's driving VVOS

  • Improving revenue and losses plus Nasdaq compliance reduces near-term listing risk, but very low cash and weaker gross margin keep downside risk elevated.

    investing.com · Nov 16, 2026

  • The partnership gives Vivos exposure to SOD's pseudohypoxia test and patents, expanding its sleep‑apnea portfolio.

    finanznachrichten.de · Oct 29, 2026

  • The compliance confirmation removes a potential delisting risk, likely supporting the stock price.

    seekingalpha.com · Oct 21, 2026

  • Compliance removes a near-term negative catalyst and may support the stock price.

    SEC EDGAR 8-K · Oct 21, 2026

  • The transaction boosts balance‑sheet strength and expands Vivos’ product pipeline, which could lift the stock if the market prices in the equity increase and future revenue potential.

    stocktitan.net · Oct 19, 2026

AlphAI scores every news story that mentions VVOS with an AI model for sentiment and relevance, and aggregates insider trades from Vivos Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $VVOS

Score

SOD SCIENCES INC.: CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test

SOD Sciences and Vivos Therapeutics (VVOS) announced a strategic partnership. Vivos acquired an 11% stake in SOD and 50% ownership of its pseudohypoxia patent and test for $12M in convertible preferred stock. The companies will jointly market the ReBalU Protocol to Vivos's customers, targeting 500,000 chronic disease patients. SOD retains other patents and protocol rights.

$VVOSLowListing notice· regained compliance

Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard LITTLETON, Colo., October 21, 2026 — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (Nasdaq: VVOS), a medical device and healthcare services company

A deal gives Vivos half of a test; reaching more than 325,000 patients still depends on agreements and court approval.

Vivos Therapeutics (VVOS) closed its acquisition of a 50% interest in a pseudohypoxia test and related intellectual property from SOD Sciences. The deal includes issuing 12,000 shares of Series C Convertible Preferred Stock, expected to increase stockholders’ equity by over $10 million. The companies plan to negotiate agreements to market products through new channels, potentially expanding Vivos' market reach to over 325,000 patients.

$VVOSHighM&A· acquirer · $12M · completed

Vivos Therapeutics, Inc. (VVOS): Completion of Acquisition or Disposition of Assets

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel Transaction Expected to Add More Than $10 Million to Stockholders’ Equity

$VVOSMedM&A· acquirer · $12M · definitive

Vivos Therapeutics, Inc. (VVOS): Entry into a Material Definitive Agreement

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test Transaction Expected to Increase Stockholders’ Equity; Opens Potential Collaboration Opportunities From New Strategic Alliances LITTLETON, Colo., Oc

Referrals to Vivos’ Las Vegas sleep centers rose about threefold. Added revenue is expected in Q4.

Vivos Therapeutics (VVOS) reported a threefold increase in referrals to its Las Vegas sleep centers, expecting Q4 revenue growth. The company targets $3.6M in annual savings by Q4 2026 and projects $1.5M-$3.0M from EEG initiatives, $3.5M from remote monitoring by Q1 2027, and $2.4M-$5.6M from payer contract renegotiations. Management aims for positive cash flow by late 2026 and profitability in 2027.

Vivos Therapeutics, Inc. (VVOS): Entry into a Material Definitive Agreement

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously reported, Vivos Therapeutics, Inc. (the “Company”) previously sold and issued to Streeterville Capital, LLC, a Utah limited liability company (“Streeterville”), a Secured Promissory Note with an original issuance

Related tickers